JNJ · Johnson & Johnson
AI read · Neutral
The AI's read
The higher full-year outlook and rising sales point to continued business growth. Cancer drugs also drove growth, but adjusted profit fell, and the Firefly and Sail deals are expected to cut 2027 adjusted profit by $1.36 per share. Stelara declines and weaker cardiovascular and surgery sales outside the U.S. add to the mixed picture, so the report does not clearly change JNJ's outlook.